International Journal of Molecular Sciences 2018, 19:E277.
This is the first published report on our proprietary compound NEO214. It characterizes the therapeutic potential of this compound in cell culture models of multiple myeloma, a disease of certain types of white blood cells. In the U.S. about 30,000 new cases are diagnosed and nearly 13,000 patients die each year. In our study, NEO214 showed strong cell killing activity against myeloma cells, but was not toxic against normal non-cancerous cells.